Cationic liposomes containing mycobacterial lipids: A new powerful Th1 adjuvant system

Infection and Immunity

Volumn 73, Issue 9, 2005, Pages 5817-5826

  Rosenkrands, Ida ^a   Agger, Else Marie ^a   Olsen, Anja W ^a   Korsholm, Karen S ^a   Andersen, Claire Swetman ^a   Jensen, Klaus T ^a   Andersen, Peter ^a  

^a STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; 3BETA N (DIMETHYLAMINOETHYL)CARBAMATE; ANTIGEN 85B ESAT 6 FUSION PROTEIN; BCG VACCINE; CATION; DIMETHYLDIOCTADECYLAMMONIUM BROMIDE; DIOLEOYLPHOSPHATIDYLETHANOLAMINE; FREUND ADJUVANT; GAMMA INTERFERON; HYBRID PROTEIN; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOLOGICAL ADJUVANT; LIPID; LIPOSOME; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLGLYCEROL; RECOMBINANT PROTEIN; TETANUS TOXOID; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; BACTERIAL CELL WALL; CHLAMYDIA; CONTROLLED STUDY; DRUG FORMULATION; FEMALE; IMMUNE RESPONSE; IMMUNOSTIMULATION; INTERFERON PRODUCTION; MEMORY CELL; MOUSE; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; RABBIT; SIGNAL TRANSDUCTION; TH1 CELL; TH2 CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; CHROMATOGRAPHY, THIN LAYER; IMMUNOLOGIC MEMORY; LIPIDS; LIPOSOMES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MYCOBACTERIUM BOVIS; TH1 CELLS; TUBERCULOSIS;

EID: 23944460116     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.73.9.5817-5826.2005     Document Type: Article

References (43)

1. Andersen, P. 1994. Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins. Infect. Immun. 62:2536-2544.
2. Andersen, P., D. Askgaard, L. Ljungqvist, J. Bennedsen, and I. Heron. 1991. Proteins released from Mycobacterium tuberculosis during growth. Infect. Immun. 59:1905-1910.
3. Andersen, P., D. Askgaard, L. Ljungqvist, M. W. Bentzon, and I. Heron. 1991. T-cell proliferative response to antigens secreted by Mycobacterium tuberculosis. Infect. Immun. 59:1558-1563.
4. Azuma, I., and T. Seya. 2001. Development of immunoadjuvants for immunotherapy of cancer. Int. Immunopharmacol. 1:1249-1259.
5. Baldridge, J. R., C. W. Cluff, J. T. Evans, M. J. Lacy, J. R. Stephens, V. G. Brookshire, R. Wang, J. R. Ward, Y. M. Yorgensen, D. H. Persing, and D. A. Johnson. 2002. Immunostimulatory activity of aminoalkyl glucosaminide 4-phosphates (AGPs): induction of protective innate immune responses by RC-524 and RC-529. J. Endotoxin Res. 8:453-458.
6. Baldridge, J. R., P. McGowan, J. T. Evans, C. Cluff, S. Mossman, D. Johnson, and D. Persing. 2004. Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert Opin. Biol. Ther. 4:1129-1138.
7. Bast, R. C., Jr., B. Zbar, T. Borsos, and H. J. Rapp. 1974. BCG and cancer. N. Engl. J. Med. 290:1458-1469.
8. Begum, N. A., K. Ishii, M. Kurita-Taniguchi, M. Tanabe, M. Kobayashi, Y. Moriwaki, M. Matsumoto, Y. Fukumori, I. Azuma, K. Toyoshima, and T. Seya. 2004. Mycobacterium bovis BCG cell wall-specific differentially expressed genes identified by differential display and cDNA subtraction in human macrophages. Infect. Immun. 72:937-948.
9. Mlum, H., H. Beier, and H. J. Gross. 1987. Improved silver staining of plant proteins, RNA and DNA in polyacrylamide gels. Electrophoresis 8:93-99.
10. Brandt, L., M. Elhay, I. Rosenkrands, E. B. Lindblad, and P. Andersen. 2000. ESAT-6 subunit vaccination against Mycobacterium tuberculosis. Infect. Immun. 68:791-795.
11. Charles, P. C., K. S. Weber, B. Cipriani, and C. F. Brosnan. 1999. Cytokine, chemokine and chemokine receptor mRNA expression in different strains of normal mice: implications for establishment of a Th1/Th2 bias. J. Neuroimmunol. 100:64-73.
12. Choquet, C. G., G. B. Patel, T. J. Beveridge, and G. D. Sprott. 1994. Stability of pressure-extruded liposomes made from atchaeobacterial ether lipids. Appl. Microbiol. Biotechnol. 42:375-384.
13. Dobson, G., D. E. Minnikin, S. M. Minnikin, J. H. Parlett, M. Goodfellow, M. Ridell, and M. Magnusson. 1985. Systematic analysis of complex mycobacterial lipids, p. 237-265. In M. Goodfellow and D. E. Minnikin (ed.), Chemical methods in bacterial systematics, vol. 1. Academic Press, London, United Kingdom.
14. European Medicines Agency. 2004. Guideline on adjuvants in vaccines for human use. European Medicines Agency, London, United Kingdom. [Online.] http://www.emea.eu.int/pdfs/human/veg/001703en.pdf.
15. Freund, J. 1956. The mode of action of immunologic adjuvants, p. 130-148. In H. Birkhäuser, Advances in tuberculosis research. Karger, Basel, Switzerland.
16. Hemmi, H., O. Takeuchi, T. Kawai, T. Kaisho, S. Sato, H. Sanjo, M. Matsumoto, K. Hoshino, H. Wagner, K. Takeda, and S. Akira. 2000. A Toll-like receptor recognizes bacterial DNA. Nature 408:740-745.
17. Higuchi, S., M. Suga, A. M. Dannenberg, Jr., L. F. Affronti, I. Azuma, T. M. Daniel, and J. P. Petrali. 1981. Persistence of protein, carbohydrate and wax components of tubercle bacilli in dermal BCG lesions. Am. Rev. Respir. Dis. 123:397-401.
18. Hilgers, L. A., and H. Snippe. 1992. DDA as an immunological adjuvant. Res. Immunol. 143:494-503.
19. Holten-Andersen, L., T. M. Doherty, K. S. Korsholm, and P. Andersen. 2004. Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines. Infect. Immun. 72:1608-1617.
20. Huang, L. Y., J. Aliberti, C. A. Leifer, D. M. Segal, A. Sher, D. T. Golenbock, and B. Golding. 2003. Heat-killed Brucella abortus induces TNF and IL-12p40 by distinct MyD88-dependent pathways: TNF, unlike IL-12p40 secretion, is Toll-like receptor 2 dependent. J. Immunol. 171:1441-1446.
21. Iwasaki, A., and R. Medzhitov. 2004. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5:987-995.
22. Katz, D., S. Lehrer, O. Galan, B. Lachmi, S. Cohen, I. Inbar, I. Samina, B. Peleg, D. Heller, H. Yadin, D. Chai, E. Freeman, H. Schupper, and P. Fuchs. 1996. Unique immunomodulating properties of dimethyl dioctadecyl ammonium bromide (DDA) in experimental viral vaccines. Adv. Exp. Med. Biol. 397:115-125.
23. Klinguer-Hamour, C., C. Libon, H. Plotnicky-Gilquin, M. C. Bussat, L. Revy, T. Nguyen, J. Y. Bonnefoy, N. Corvaia, and A. Beck. 2002. DDA adjuvant induces a mixed Th1/Th2 immune response when associated with BBG2Na, a respiratory syncytial virus potential vaccine. Vaccine 20:2743-2751.
24. Koike, Y., Y. C. Yoo, M. Mitobe, T. Oka, K. Okuma, S. Tono-oka, and I. Azuma. 1998. Enhancing activity of mycobacterial cell-derived adjuvants on immunoganicity of recombinant human hepatitis B virus vaccine. Vaccine 16:1982-1989.
25. Krishnan, L., C. J. Dicaire, G. B. Patel, and G. D. Sprott. 2000. Archaeosome vaccine adjuvants induce strong humoral, cell-mediated, and memory responses: comparison to conventional liposomes and alum. Infect. Immun. 68:54-63.
26. + cytotoxic T cell response to entrapped soluble protein by the exogenous cytosolic pathway, in the absence of CD4+ T cell help. J. Immunol. 165:5177-5185.
27. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
28. + cell-depleted BALB/c mice. J. Virol. 70:3084-3092.
29. Lemieux, P. 2002. Technological advances to increase immunogenicity of DNA vaccines. Expert Rev. Vaccines 1:85-93.
30. McBride, B. W., A. Mogg, J. L. Telfer, M. S. Lever, J. Miller, P. C. Turnbull, and L. Baillie. 1998. Protective efficacy of a recombinant protective antigen against Bacillus anthracis challenge and assessment of immunological markers. Vaccine 16:810-817.
31. Moingeon, P., J. Haensler, and A. Lindberg. 2001. Towards the rational design of Th1 adjuvants. Vaccine 19:4363-4372.
32. O'Hagan, D. T., and N. M. Valiante. 2003. Recent advances in the discovery and delivery of vaccine adjuvants. Nat. Rev. Drug Discov. 2:727-735.
33. Olsen, A. W., L. A. H. vanPinxteren, L. M. Okkels, P. B. Rasmussen, and P. Andersen. 2001. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Infect. Immun. 69:2773-2778.
34. Pulendran, B. 2004. Modulating vaccine responses with dendritic cells and Toll-like receptors. Immunol. Rev. 199:227-250.
35. Raffel, S., L. E. Arnaud, C. D. Dukes, and J. S. Huang. 1949. The role of the "wax" of the tubercle bacillus in establishing delayed hypersensitivity. II. Hypersensitivity to a protein antigen, egg albumin. J. Exp. Med. 90:53-72.
36. Reed, M. B., P. Domenech, C. Manca, H. Su, A. K. Barczak, B. N. Kreiswirth, G. Kaplan, and C. E. Barry, 3rd. 2004. A glycolipid of hypervirulent tuberculosis strains that inhibits the innate immune response. Nature 431:84-87.
37. Sprott, G. D., C. J. Dicaire, K. Gurnani, S. Sad, and L. Krishnan. 2004. Activation of dendritic cells by liposomes prepared from phosphatidylinositol mannosides from Mycobacterium bovis bacillus Calmette-Guerin and adjuvant activity in vivo. Infect. Immun. 72:5235-5246.
38. Suzuki, F., R. R. Brutkiewicz, and R. B. Pollard. 1986. Importance of Lyt 1+ T-cells in the antitumor activity of an immunomodulator, SSM, extracted from human-type Tubercle bacilli. J. Natl. Cancer Inst. 77:441-447.
39. Theisen, M., S. Soe, K. Brunstedt, F. Follmann, L. Bredmose, H. Israelsen, S. M. Madsen, and P. Druilhe. 2004. A Plasmodium falciparum GLURP-MSP3 chimeric protein; expression in Lactococcus lactis, immunogenicity and induction oi biologically active antibodies. Vaccine 22:1188-1198.
40. Theisen, M., J. Vuust, A. Gottschau, S. Jepsen, and B. Høgh. 1995. Antigenicity and immunogenicity of recombinant glutamate-rich protein of Plasmodium falciparum expressed in Eschericia coli. Clin. Diagn. Lab. Immunol. 2:30-34.
41. Veronesi, R., A. Correa, and D. Alterio. 1970. Single dose immunization against tetanus. Promising results in human trials. Rev. Inst. Med. Trop. Sao Paulo 12:46-54.
42. Yotnda, P., D. H. Chen, W. Chiu, P. A. Piedra, A. Davis, N. S. Templeton, and M. K. Brenner. 2002. Bilamellar cationic liposomes protect adenovectors from preexisting humoral immune responses. Mol. Ther. 5:233-241.
43. Zuhorn, I. S., and D. Hoekstra. 2002. On the mechanism of cationic amphiphile-mediated transfection. To fuse or not to fuse: is that the question? J. Membr. Biol. 189:167-179.